Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $102.36 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Volitionrx Ltd had its IPO on 2007-04-25 under the ticker symbol VNRX.
The company operates in the Healthcare sector and Diagnostics & Research industry. Volitionrx Ltd has a staff strength of 111 employees.
Shares of Volitionrx Ltd opened at $1.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.3 - $1.38, and closed at $1.34.
This is a +2.29% increase from the previous day's closing price.
A total volume of 150,609 shares were traded at the close of the day’s session.
In the last one week, shares of Volitionrx Ltd have increased by +3.88%.
Volitionrx Ltd's Key Ratios
Volitionrx Ltd has a market cap of $102.36 million, indicating a price to book ratio of 35.2345 and a price to sales ratio of 563.9999.
In the last 12-months Volitionrx Ltd’s revenue was $518547 with a gross profit of $306392 and an EBITDA of $-33550996. The EBITDA ratio measures Volitionrx Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Volitionrx Ltd’s operating margin was -6672.04% while its return on assets stood at -83.32% with a return of equity of -730.06%.
In Q2, Volitionrx Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 444.1%.
Volitionrx Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Volitionrx Ltd’s profitability.
Volitionrx Ltd stock is trading at a EV to sales ratio of 518.863 and a EV to EBITDA ratio of -3.4691. Its price to sales ratio in the trailing 12-months stood at 563.9999.
Volitionrx Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $27.56 million
- Total Liabilities
- $18.80 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Volitionrx Ltd ended 2023 with $27.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $27.56 million while shareholder equity stood at $5.84 million.
Volitionrx Ltd ended 2023 with $0 in deferred long-term liabilities, $18.80 million in other current liabilities, 78137.00 in common stock, $-185507956.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.74 million and cash and short-term investments were $19.74 million. The company’s total short-term debt was $1,464,947 while long-term debt stood at $2.45 million.
Volitionrx Ltd’s total current assets stands at $21.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $196487.00 compared to accounts payable of $3.49 million and inventory worth $1.02 million.
In 2023, Volitionrx Ltd's operating cash flow was $-301394.00 while its capital expenditure stood at $301394.
Comparatively, Volitionrx Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Volitionrx Ltd stock is currently trading at $1.34 per share. It touched a 52-week high of $2.74 and a 52-week low of $2.74. Analysts tracking the stock have a 12-month average target price of $4.86.
Its 50-day moving average was $1.31 and 200-day moving average was $1.78 The short ratio stood at 4.64 indicating a short percent outstanding of 0%.
Around 2417.2% of the company’s stock are held by insiders while 824.8% are held by institutions.
Frequently Asked Questions About Volitionrx Ltd
Similar Industry Stocks (Diagnostics & Research)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.